Navigation Links
AMDL Receives a Significant Updated Appraisal of Its JJB China Production Facilities
Date:2/4/2008

TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. The Company announced today that JPI's subsidiary JJB received an updated third party valuation of its land use rights, plant and buildings that have been now been reappraised for a total of approximately $21.8 million, significantly above the FY2007 book value of these assets.

Frank Zheng, Managing Director of Jade, stated that "This new appraisal by the accounting firm of Jiangxi Zhong Cheng Accounting Co., Ltd., is anticipated to provide JJB with the ability to significantly expand its current credit facilities, including gaining larger credit facilities under more favorable interest rates."

Mr. Gary Dreher, CEO of AMDL noted that "this new appraisal is another illustration of the significant value that JPI's business brings to AMDL in 2008 and beyond."

About Jade Pharmaceutical Inc.: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program ... of his grandfather, “Hire for attitude. Train for skill.” , In keeping with this ... Jevohn Miller as a salesman. Zamzow is hoping to replicate the practice throughout the ...
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Chef Jodi ... wine scene. Making stops in several cities, she gained a number of delicious ... began in Stellenbosch, a town in South Africa’s Western Cape province. It is ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
Breaking Biology Technology:
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
Breaking Biology News(10 mins):